Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04995341 · ClinicalTrials.gov registry record · NA

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

A NA study of Retinopathy of Prematurity, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
236
Enrollment target
2
Study locations

NCT04995341: Recruiting NA study of Retinopathy of Prematurity, sponsored by Duke University.

NCT04995341 is a NA study of Retinopathy of Prematurity that is actively recruiting participants, run by Duke University. The registered enrollment target is 236 participants, below the 335-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (30% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04995341, a NA study of Retinopathy of Prematurity, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
236 participants
Enrollment target
2
Study locations

Study Summary

Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. This study tests high-speed optical coherence tomography (OCT) technology compared to conventional color photographs at the bedside of very preterm infants in the intensive care nursery, to characterize previously unseen abnormalities that can predict a need for referral for ROP treatment, or poor visual or neurological development later in life, up to pre-school age. Our long-term goal is to help improve preterm infant health and vision via objective bedside imaging and analysis that characterizes early critical indicators of ROP, and poor visual function and neurological development, which will rapidly translate to better early intervention and improved future care.

Primary Outcome

HOTV visual acuity at the 5-year study visit. Visual acuity is recorded as the last line of the HOTV chart on which over 50% of the 4 symbols are identified correctly identified by the participant. If the participant is not capable of performing HOTV, then Teller cards will be used for preferential-looking visual acuity assessment. With Teller, acuity is determined by the smallest cycles per degree.

Conditions Studied

Interventions

  • DEVICE Investigational ultracompact OCT and OCTA system
  • DEVICE retinal photographs

Study Locations (2)

North Carolina

  • Duke University Eye Center - Durham

Pennsylvania

  • University of Pennsylvania, Center for Preventive Ophthalmology and Biostatistics - Philadelphia

Trial Details

FieldValue
Enrollment Target 236 participants
Start Date 2021-08-16
Est. Completion 2026-03-31
Phase NA
Duke University

1,725 total trials

What NCT04995341 shows while recruiting

NCT04995341 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, below the 335-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (30% lower).

The record links to 1 condition, with Retinopathy of Prematurity appearing as the primary indexed condition, and to 2 interventions - of which Investigational ultracompact OCT and OCTA system is the first listed.

NCT04995341 reports a single indexed study location in North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04995341 about?

NCT04995341 is a clinical study titled "Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)". Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. This study tests high-speed optical coherence tomography (OCT) technology compared to conventional color photographs at the bed...

What is the current status of trial NCT04995341?

This trial is currently recruiting. It is a NA study. The enrollment target is 236 participants. The study started on 2021-08-16. Estimated completion is 2026-03-31.

What conditions does trial NCT04995341 study?

This clinical trial studies the following conditions: Retinopathy of Prematurity.

What interventions are being tested in trial NCT04995341?

The interventions under investigation include: Investigational ultracompact OCT and OCTA system (DEVICE), retinal photographs (DEVICE).

Who is sponsoring clinical trial NCT04995341?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04995341 being conducted?

This trial has 2 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Retinopathy of Prematurity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05822362 · 236 participants · Phase 2

    CBD for Individuals at Risk for Alzheimer's Disease

  • NCT06200103 · 236 participants · Phase 2

    Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

  • NCT06494072 · 236 participants · Phase 4

    Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

  • NCT06615557 · 236 participants · Phase 3

    Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04995341, the US trial registry maintained by the National Library of Medicine. NCT04995341 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.